SLC5A2 and type 2 diabetes mellitus: Additionally, insulin and SGLT2-inhibitor-users also had higher COMPASS-31 scores, but these are not first-line treatments for T2D suggesting a longer disease duration and potentially poorer glycemic control contributing to the COMPASS-31 score and not necessarily the medication on its own.